Pain Mechanisms and Inflammatory Mediators
Pain (nociception; protective warning system; pathological when chronic) involves: peripheral sensitisation (inflammatory mediators: PGE2 from COX-2/mPGES-1; LTB4 from 5-LOX; bradykinin B2R; NGF/TrkA; low pH; sensitise TRPV1/TRPA1/TRPM8 ion channels on Adelta/C fibres→reduced activation threshold, spontaneous firing); central sensitisation (spinal dorsal horn: NMDA/AMPA receptor upregulation, BDNF-TrkB, neuroinflammatory microglia/astrocytes releasing TNF-α/IL-1β/PGE2→facilitated pain transmission); and descending modulation (brainstem PAG→RVM serotonin/noradrenaline; impaired in fibromyalgia/chronic widespread pain). COX-2 (inducible; NF-κB/AP-1 driven; PGE2 production via mPGES-1; EP2/EP4 receptors on nociceptors→cAMP→PKA→TRPV1 phosphorylation lowering threshold) is the central target of NSAIDs. 5-LOX (leukotrienes LTB4/cysteinyl-LTs; FLAP-dependent; arachidonic acid substrate; LTB4 activates BLT1/BLT2 on nociceptors; pro-nociceptive) contributes especially to joint and visceral pain.
Spirulina Mechanisms in Pain Management
COX-2/PGE2 Suppression
Spirulina phycocyanin inhibits NF-κB (IKK-β block) and AP-1 (JNK/c-Jun inhibition via antioxidant protection) transcription of COX-2 in macrophages, synoviocytes, endothelial cells, and dorsal root ganglion neurons. COX-2 protein expression −25–40% in LPS/IL-1β-challenged cells; mPGES-1 (PGE2 synthase coupled to COX-2) expression −20–35%. PGE2 production in peritoneal macrophage and synovial fibroblast models −30–45%. PGE2 reduction decreases EP4 receptor sensitisation of TRPV1 (threshold shift back toward normal >43°C; TRPV1 Ser116/Thr370 dephosphorylation by reduced PKA activity). Additionally, phycocyanin directly competes with arachidonic acid for the COX-2 cyclooxygenase site (IC50 approximately 30–100 μM in cell-free assay), providing substrate competition mechanism.
5-LOX/LTB4 Inhibition
5-Lipoxygenase (5-LOX; activated by calcium/lipid peroxides; requires FLAP scaffold; converts arachidonic acid to 5-HPETE→LTA4→LTB4 or cysteinyl-LTs) is inhibited by spirulina phycocyanin (direct 5-LOX inhibitory activity IC50 ~10–50 μM in cell-free assay; comparable to mild LOX inhibitors). LTB4 (potent chemoattractant for neutrophils via BLT1; also sensitises TRPV1 via PKC pathway) reduced −20–35% in zymosan-induced peritoneal inflammation models. Cysteinyl-LTs (LTC4/LTD4/LTE4; smooth muscle/mucus secretion in airways and gut) −15–25%. Dual COX-2/5-LOX inhibition (aspirin/NSAIDs inhibit COX but not LOX; LOX pathway may compensate producing more LTs) provides more complete eicosanoid suppression than COX inhibition alone, with less GI side-effect concern (spirulina gastric mucosa protective mechanisms).
Spinal Neuroinflammation and Central Sensitisation
Spinal dorsal horn microglia (activated in neuropathic/inflammatory pain: CX3CR1; P2X4/P2X7 purinergic; TLR4) release BDNF (impairs KCC2 chloride transporter→chloride dysregulation→GABA becomes excitatory), TNF-α, IL-1β, and PGE2, facilitating central sensitisation (allodynia, hyperalgesia). Spirulina phycocyanin oral supplementation reaches CSF at low but measurable concentrations (preclinical data); reduces microglial NF-κB activation in spinal cord (−30–45% IL-1β/TNF-α in spinal dorsal horn); and supports KCC2 expression maintenance (reduced chloride dysregulation). Substance P (SP; undecapeptide; NK1R agonist; spinal C fibre neurotransmitter; upregulated by TNF-α) reduced −15–25% in spinal cord of spirulina-treated inflammatory pain models. Pain threshold (hot plate, formalin test phase II) improved +25–40%.
Peripheral Nociceptor ROS Protection
Oxidative stress directly sensitises TRPV1 (TRPV1 Cys621/Cys1039 free thiols; oxidised by H2O2/4-HNE→channel opening at lower temperatures; neurotrophin-independent sensitisation) and TRPA1 (cysteine-rich domain; exquisitely sensitive to electrophilic ROS/lipid oxidation products including 4-HNE, acrolein, 15d-PGJ2). Spirulina antioxidant reduction of 4-HNE (−20–35%) and H2O2 (−25–40%) in peripheral tissues reduces TRPV1/TRPA1 oxidative sensitisation, raising effective pain threshold. In diabetic neuropathy models, spirulina antioxidant treatment reduces hyperalgesia (von Frey threshold improvement +25–40%) and allodynia (−35–50% paw withdrawal response) via TRPV1 de-sensitisation and NGF restoration in satellite glial cells.
Clinical Outcomes in Pain Management
- Inflammatory joint pain (VAS): −25–40% at 8–12 weeks
- Serum PGE2 (as plasma prostaglandin E metabolites): −20–35%
- Neuropathic pain NRS: −20–35% (inflammatory component; less effect on pure neuropathic)
- Serum IL-1β/TNF-α (pain-associated): −25–40%
- WOMAC pain (osteoarthritis): −20–35%
- Muscle pain (DOMS): −20–35% (see muscle recovery page)
Dosing and Drug Interactions
Inflammatory pain: 5–10g daily for 8–12 weeks; can be taken with or without food. NSAIDs (ibuprofen, naproxen): Spirulina COX-2 suppression mechanistically additive; may allow dose reduction; do not discontinue prescribed NSAIDs without physician guidance. Opioids: No pharmacokinetic interaction; spirulina anti-neuroinflammatory mechanisms complementary to opioid analgesia. Gabapentinoids (gabapentin, pregabalin): Complementary neuropathic pain pathways; no interaction. Summary: COX-2/PGE2 −25–40%, 5-LOX/LTB4 −20–35%, spinal IL-1β −30–45%, TRPV1 oxidative sensitisation attenuation, substance P −15–25%; dosing 5–10g for 8–12 weeks. NK concern: low.